Global Intranasal Drug Delivery Market 2014-2018

About Intranasal Drug Delivery
Intranasal drug delivery system is a medical device used for the administration of drugs for the treatment of local diseases in the nose and paranasal sinus such as allergic and non-allergic rhinitis and sinusitis. The nose is considered to be an ideal administrative route for needle-free vaccination and systematic drug delivery. Continuous technological advancement is being made in intranasal drug delivery product to achieve efficient treatment facility. Intranasal drug delivery system plays a major role in improving the quality of the life of patients, by providing an easy mode of drug administration for patients on long-term therapy, as well as low risk of overdose and enhanced bioavailability.

TechNavio's analysts forecast the Global Intranasal Drug Delivery market to grow at a CAGR of 2.92 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Intranasal Drug Delivery market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of the following intranasal drug delivery systems:
‧ Nasal spray
‧ Nasal drop
‧ Nasal powder
‧ Nasal gel
‧ Nasal vaccine
TechNavio's report, the Global Intranasal Drug Delivery market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Intranasal Drug Delivery market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
‧ Americas
‧ APAC
‧ EMEA
Key Vendors
‧ Becton, Dickinson and Company
‧ GlaxoSmithKline
‧ Johnson & Johnson
‧ Novartis
Other Prominent Vendors

‧ Actiza Pharmaceutical
‧ Aptar Group
‧ Korten Pharmaceuticals
‧ OptiNose
‧ Patheon
‧ Vee Remedies
‧ Zymeth Wellness
Market Driver
‧ Increase in Aging Population
‧ For a full, detailed list, view our report
Market Challenge
‧ Risk of Over Dosage and Side Effects
‧ For a full, detailed list, view our report
Market Trend
‧ Increased Adoption of Non-invasive Products
‧ For a full, detailed list, view our report
Key Questions Answered in this Report
‧ What will the market size be in 2018 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.1.1 Market Size and Forecast
06.2 Five Forces Analysis
07. Market Segmentation by Product
07.1 Global Intranasal Drug Delivery market by Product 2013-2018
08. Geographical Segmentation
08.1 Global Intranasal Drug Delivery Market by Geographical Segmentation 2013-2018
08.1.1 Market Size and Forecast
08.2 Intranasal Drug Delivery Market in the Americas
08.2.1 Market Size and Forecast
08.3 Intranasal Drug Delivery Market in the EMEA Region
08.3.1 Market Size and Forecast
08.4 Intranasal Drug Delivery Market in the APAC Region
08.4.1 Market Size and Forecast
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.2 Market Share Analysis 2013
16.3 Other Prominent Vendors
17. Key Vendor Analysis
17.1 Becton, Dickinson and Co.
17.1.1 Key Facts
17.1.2
17.1.3 Business Description
17.1.4 Business Segmentation
17.1.5 Revenue Segmentation by Business
17.1.6 Segmental Revenue Comparison - 2013 and 2012
17.1.7 Revenue Segmentation by Geography
17.1.8 Business Strategy
17.1.9 Key Developments
17.2 SWOT Analysis
17.2.1 SWOT Overview
17.2.2 Strengths
17.2.3 Weakness
17.2.4 Opportunities
17.2.5 Threats
17.3 GlaxoSmithKline plc
17.3.1 Key Facts
17.3.2 Business Overview
17.3.3 Business Segmentation
17.3.4 Business Segmentation by Revenue 2012 and 2013
17.3.5 Sales by Geography
17.3.6 Pipeline Products
17.3.7 Business Strategy
17.3.8 Key Information
17.3.9 SWOT Analysis
17.3.10 Strengths
17.3.11 Weaknesses
17.3.12 Opportunities
17.3.13 Threats
17.4 Johnson & Johnson
17.4.1 Key Facts
17.4.2 Business Overview
17.4.3 Business Segmentation by Revenue 2013
17.4.4 Business Segmentation by Revenue 2012 and 2013
17.4.5 Geographical Segmentation by Revenue 2013
17.4.6 Business Strategy
17.4.7 Recent Developments
17.4.8 SWOT Analysis
17.4.9 Strengths
17.4.10 Weaknesses
17.4.11 Opportunities
17.4.12 Threats
17.5 Novartis AG
17.5.1 Key Facts
17.5.2 Business Overview
17.5.3 Business Segmentation by Revenue 2013
17.5.4 Business Segmentation by Revenue 2012 and 2013
17.5.5 Sales by Geography
17.5.6 Business Strategy
17.5.7 Key Developments
17.6 SWOT Analysis
17.6.1 Strengths
17.6.2 Weaknesses
17.6.3 Opportunities
17.6.4 Threats




List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Intranasal Drug Delivery Market 2013-2018 (US$ million)
Exhibit 3: Global Intranasal Drug Delivery Market Segmentation by Product Type
Exhibit 4: Global Intranasal Drug Delivery Market by Geographical Segmentation 2013
Exhibit 5: Global Intranasal Drug Delivery Market by Geographical Segmentation 2013-2018
Exhibit 6: Intranasal Drug Delivery Market in the Americas Region 2013-2018 (US$ million)
Exhibit 7: Intranasal Drug Delivery Market in the EMEA Region 2013-2018 (US$ million)
Exhibit 8: Intranasal Drug Delivery Market in the APAC Region 2013-2018 (US$ million)
Exhibit 9: Product Categorization of Becton, Dickinson and Co.
Exhibit 10: Revenue Segmentation of Becton, Dickinson and Co. 2013
Exhibit 11: Revenue Comparison (US$ million)
Exhibit 12: Revenue Segmentation of Becton, Dickinson and Co. by Geography 2013
Exhibit 13: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 14: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 15: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 16: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 17: Johnson & Johnson: Business Segmentation by Revenue 2013
Exhibit 18: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 19: Johnson & Johnson: Geographical Segmentation by Revenue 2013
Exhibit 20: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 21: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 22: Novartis AG: Sales by Geography 2013